Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MyMD Pharmaceuticals, Inc. (AKER)
|
Add to portfolio |
|
|
|
| Price: |
$2.96
| | Metrics |
| OS: |
44.9
|
M
| |
|
|
| Market cap: |
$133
|
M
| |
|
|
|
Net cash:
|
$13.1
|
M
| |
$0.29
|
per share
|
|
EV:
|
$120
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | -0.7 | -15.6 | -4.1 | -0.1 | 1.7 | 3.4 | 3.0 | 2.1 |
| Revenue growth | -95.6% | 285.7% | 3746.9% | -106.3% | -50.4% | 13.3% | 40.0% | -52.2% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | -6.8 | 1.5 | 2.4 | 1.1 | 1.0 |
| Gross profit | -0.7 | -15.6 | -4.1 | 6.7 | 0.1 | 0.9 | 1.9 | 1.2 |
| Gross margin | 100.0% | 100.0% | 100.0% | -6362.1% | 7.6% | 28.3% | 63.4% | 55.0% |
| Sales and marketing | | | | 0.0 | 1.8 | 2.0 | 2.0 | 2.5 |
| Research and development | 9.1 | 6.7 | 2.5 | | 1.1 | 1.3 | 1.2 | 1.4 |
| General and administrative | 5.5 | 6.4 | 2.9 | 3.4 | 5.7 | 4.1 | 3.0 | 4.0 |
| EBITA | -15.3 | -28.8 | -9.5 | -3.5 | -9.0 | -6.4 | -3.2 | -9.4 |
| EBITA margin | 2198.4% | 184.2% | 233.5% | 3284.0% | -541.4% | -192.0% | -106.6% | -446.6% |
| Amortization of intangibles | | | 0.0 | | 0.2 | 0.2 | 0.2 | 0.2 |
| EBIT | -15.3 | -28.8 | -9.5 | -3.5 | -9.2 | -6.6 | -3.3 | -9.7 |
| EBIT margin | 2198.4% | 184.2% | 233.9% | 3284.0% | -551.6% | -197.1% | -112.4% | -457.8% |
| Pre-tax income | -15.2 | -29.9 | -9.5 | -3.4 | -10.8 | -7.4 | -3.3 | -9.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | -0.3 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 2.8% |
| Earnings from continuing ops | -15.2 | -29.9 | -9.5 | -2.9 | -10.8 | -7.4 | -3.3 | -9.3 |
| Earnings from discontinued ops | | | | -0.5 | | | | |
| Net income | -15.2 | -29.9 | -9.5 | -3.4 | -10.8 | -7.4 | -3.3 | -9.3 |
| Net margin | 2186.1% | 191.1% | 233.9% | 3207.0% | -651.4% | -219.6% | -111.6% | -440.3% |
| |
| Diluted EPS | ($0.39) | ($0.85) | ($0.34) | ($4.69) | ($22.28) | ($6.29) | ($0.61) | ($1.81) |
| Shares outstanding (diluted) | 38.8 | 35.0 | 28.2 | 0.6 | 0.5 | 1.2 | 5.4 | 5.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|